OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
20 Avril 2023 - 7:30AM
Business Wire
At the 2023 American Association for Cancer
Research (AACR) Annual Meeting
- CLEC-1 inhibitory myeloid checkpoint blockade enhances
antitumor responses and tumor phagocytosis by macrophages.
- TRIM21 has been identified by OSE Immunotherapeutics in
collaboration with Dr Elise Chiffoleau’s team (1) as a novel
interaction partner for CLEC-1, and the CLEC-1/TRIM21 axis as a new
target for cancer immunotherapy.
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE) presented two additional posters reporting the latest
research updates on CLEC-1 (new myeloid immune checkpoint), from
its Myeloid platform, at the 2023 American Association for Cancer
Research (AACR) Annual Meeting held in Orlando (Florida) on April
14-19.
CLEC-1, novel myeloid immune checkpoint target
The academic collaboration conducted with Dr Elise Chiffoleau’s
team at the Center for Translational Research in Transplantation
and Immunology (1) has led to identify CLEC-1 as a checkpoint, a
receptor expressed by myeloid cells inhibiting key pro-phagocytic
and T-cell cross-priming functions and hence limiting anti-tumor
immune responses.
Dr Aurore Morello, Head of Research of OSE Immunotherapeutics,
comments: “Altogether, the data presented at the AACR meeting
demonstrate that CLEC-1 acts as a new immune checkpoint in myeloid
cells and highlight the CLEC-1/new ligand TRIM21 axis as a new
target for cancer immunotherapy. These latest data generated from
our teams’ collaboration provide evidence to further support the
preclinical evaluation of monoclonal antagonist antibodies
targeting CLEC-1. Importantly, this opens the way for further
upcoming translational clinical studies aiming at developing a new
myeloid immune checkpoint therapy releasing the breaks on
macrophages and dendritic cells.”
“CLEC-1 inhibitory myeloid checkpoint blockade enhances
antitumor responses and tumor phagocytosis by macrophages”.
CLEC-1 blockade with proprietary monoclonal antibodies increases
tumor rejection in monotherapy and synergizes with chemotherapy.
Anti-CLEC-1 monoclonal antibodies profoundly impacted the tumor
environment: frequencies of invigorated dendritic cells and
macrophages, activated cells and memory T-cells were increased,
while frequencies of immunosuppressive myeloid cells and
PD1-expressing T-cells were largely decreased.
The findings presented also revealed a previously unrecognized
function for CLEC-1 in myeloid cells as a specific sensor of
non-homeostatic cell death. The data showed that the absence of
CLEC-1 suppresses tumor growth and hinders immunosuppressive tumor
microenvironment.
“TRIM21 is a novel endogenous partner of the inhibitory
myeloid checkpoint CLEC-1 involved in tumor antigen
cross-presentation”.
TRIM21, an intra-cellular Fc receptor and E3 ubiquitin ligase,
is identified as a novel interaction partner for CLEC-1 (a
discovery published in ‘Sciences Advances’ last November: Drouin et
al., 2022). The research demonstrated the functional relevance of
CLEC-1 interaction with its ligand. High TRIM21 expression is
predictive of worse overall survival in patients with
hepatocellular carcinoma, pancreatic cancer, or glioma.
Mechanistically, CLEC-1 inhibition enhances the capacity of
dendritic cells to cross-present tumor antigens to T lymphocytes, a
process known to be regulated by TRIM21 through its E3 ubiquitin
ligase activity. Antagonist anti-CLEC-1 or anti-TRIM21 antibodies
are therefore being evaluated to further confirm the involvement of
the newly identified CLEC-1 interaction with TRIM21 in the
regulation of CLEC-1’s function as an inhibitory myeloid
checkpoint.
(1) Collaborative academic program between OSE
Immunotherapeutics and Dr Elise Chiffoleau’s research teams (Center
for Research in Transplantation and Translational Immunology
(CR2TI), UMR1064, INSERM, Nantes University at Nantes University
Hospital, https://cr2ti.univ-nantes.fr/research/team-1).
Poster presentation details:
Poster CLEC#1
Title: “CLEC-1 inhibitory myeloid checkpoint
blockade enhances antitumor responses and tumor phagocytosis by
macrophages”” Session Category: Immunology Session
Title: Immune Checkpoints Session Date and Time: April
19, 2023 - 9:00 AM – 12:30 PM Location: Section 23 Poster
Board Number: 2
Poster CLEC#2
Title: “TRIM21 is a novel endogenous partner of the inhibitory
myeloid checkpoint CLEC-1 involved in tumor antigen
cross-presentation” Session Category: Immunology Session Title:
Immune Checkpoints Session Date and Time: April 19, 2023 - 9:00 AM
- 12:30 PM Location: Poster Section 23 Poster Board Number: 9
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is a
biotech company dedicated to developing first-in-class assets in
immuno-oncology and immuno-inflammation. The Company’s current
well-balanced first-in-class clinical pipeline includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or
lymphomas (first patient included). OSE-279 is the backbone therapy
of the BiCKI® platform.
- OSE-127/S95011 - lusvertikimab (humanized
monoclonal antibody antagonist of IL-7 receptor) developed in
partnership with Servier; ongoing Phase 2 in ulcerative colitis
(sponsor OSE Immunotherapeutics) and ongoing Phase 2a in Sj�gren’s
syndrome (sponsor Servier); ongoing pre-clinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on
CD47/SIRPα pathway) developed in partnership with Boehringer
Ingelheim in advanced solid tumors; positive Phase 1 dose
escalation results in monotherapy and in combination, in particular
with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing
clinical trial in combination with ezabenlimab alone or with other
drugs in patients with recurrent/metastatic head and neck squamous
cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).
OSE Immunotherapeutics expects to generate further significant
value from its two proprietary drug discovery platforms, which are
central to its ambitious goal to deliver next-generation
first-in-class immunotherapeutics:
- BiCKI® platform focused on immuno-oncology (IO) is a
bispecific fusion protein platform built on the key backbone
component of anti-PD1 combined with a new immunotherapy target to
increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced
BiCKI® candidate targeting anti-PD1xIL-7.
- Myeloid platform focused on optimizing the therapeutic
potential of myeloid cells in IO and immuno-inflammation (I&I).
OSE-230 (ChemR23 agonist mAb) is the most advanced candidate
generated by the platform, with the potential to resolve chronic
inflammation by driving affected tissues to tissue integrity.
Additional information about OSE Immunotherapeutics assets is
available on the Company’s website: www.ose-immuno.com Click and
follow us on Twitter and LinkedIn
Forward-looking statements This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are
based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate. These forward-looking statements include
statements typically using conditional and containing verbs such as
“expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”,
their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on 15 April 2022, including the annual financial
report for the fiscal year 2021, available on the OSE
Immunotherapeutics’ website. Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date
hereof and does not undertake any obligation to update or revise
the forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230419005752/en/
OSE Immunotherapeutics Sylvie Détry
sylvie.detry@ose-immuno.com +33 1 53 198 757
Investor Relations Thomas Guillot
thomas.guillot@ose-immuno.com +33 6 07 380 431
French Media: FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 6 07 768 283
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024